Li Zhou
Li Zhou has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Abraham C.F. Leung
11Pfizer Inc., South San Francisco, California
45 shared publications - Emiliano Calvo
START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain
45 shared publications - Funda Meric-Bernstam
Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA
45 shared publications - Giuseppe Curigliano
Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
45 shared publications - Keun Seok Lee
Center for Breast Cancer, National Cancer Center, Goyang, Republic of Korea
45 shared publications - Pavani Chalasani
Division of Hematology-Oncology, George Washington University, Washington, USA
45 shared publications
Latest Publications
- Open Access
- 12 May 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (5) , e70261
Adaptive Dosing Trial Simulation Framework to Inform Dose Optimization: Case Study Using Longitudinal PKPD Models With PF ‐06804103 Phase 1 Data in Participants With Human Epidermal Growth Factor Receptor 2 ( HER2 ) Positive and Low Solid Tumors
Population models to identify optimal dosages typically include the evaluation of a drug's pharmacokinetics and the relationships with efficacy and safety. Dose modifications due to intolerable toxicities are frequently required for oncology therapeutics taken chronically and may impact antitumor activity and subsequent occurrences of adverse events. Model‐based simulations must account for the impact of dose modifications to provide meaningful predictions that capture the dynamic interplay between pharmacokinetics, safety, and efficacy. While static dose modification schedules may be incorporated into simulations, these pre‐determined scenarios are empiric and may not adequately capture the time‐dependent and stochastic nature of adverse events that lead to dose modifications. PF‐06804103 is an anti‐HER2 antibody‐drug conjugate that demonstrated dose‐dependent antitumor activity and safety events. PF‐06804103 appeared to have a narrow therapeutic window, which made it difficult to identify the optimal starting dosing regimen and dose modification schedule. Thus, quantitative modeling approaches were explored to better understand exposure‐response relationships. An adaptive clinical trial simulation framework consisting of pharmacokinetic, tumor dynamic, and repeated time‐to‐event peripheral neuropathy longitudinal models was developed to guide the dose optimization of PF‐06804103. This framework provides the advantage of accounting for adverse event‐driven dose modifications and their real‐time impact of safety on PK and efficacy, and can be adapted to other oncology therapeutics with time‐dependent and exposure‐related safety and efficacy profiles. The framework could be particularly beneficial to inform dose optimization, by integrating multi‐dimensional early clinical data to evaluate different dosage regimens and define the regimen with the best benefit/risk ratio for further investigation.
- 12 May 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (5) , e70261
Open AccessAdaptive Dosing Trial Simulation Framework to Inform Dose Optimization: Case Study Using Longitudinal PKPD Models With PF ‐06804103 Phase 1 Data in Participants With Human Epidermal Growth Factor Receptor 2 ( HER2 ) Positive and Low Solid Tumors
Population models to identify optimal dosages typically include the evaluation of a drug's pharmacokinetics and the relationships with efficacy and safety. Dose modifications due to intolerable toxicities are frequently required for oncology therapeutics taken chronically and may impact antitumor activity and subsequent occurrences of adverse events. Model‐based simulations must account for the impact of dose modifications to provide meaningful predictions that capture the dynamic interplay between pharmacokinetics, safety, and efficacy. While static dose modification schedules may be incorporated into simulations, these pre‐determined scenarios are empiric and may not adequately capture the time‐dependent and stochastic nature of adverse events that lead to dose modifications. PF‐06804103 is an anti‐HER2 antibody‐drug conjugate that demonstrated dose‐dependent antitumor activity and safety events. PF‐06804103 appeared to have a narrow therapeutic window, which made it difficult to identify the optimal starting dosing regimen and dose modification schedule. Thus, quantitative modeling approaches were explored to better understand exposure‐response relationships. An adaptive clinical trial simulation framework consisting of pharmacokinetic, tumor dynamic, and repeated time‐to‐event peripheral neuropathy longitudinal models was developed to guide the dose optimization of PF‐06804103. This framework provides the advantage of accounting for adverse event‐driven dose modifications and their real‐time impact of safety on PK and efficacy, and can be adapted to other oncology therapeutics with time‐dependent and exposure‐related safety and efficacy profiles. The framework could be particularly beneficial to inform dose optimization, by integrating multi‐dimensional early clinical data to evaluate different dosage regimens and define the regimen with the best benefit/risk ratio for further investigation.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Table S4 shows the immunogenicity results
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Table S4 shows the immunogenicity results
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Table S1 shows the treatment-related adverse events
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Table S1 shows the treatment-related adverse events
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Table S2 shows the PK results
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Table S2 shows the PK results
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Figure S3 shows the time to and duration of response in patients with confirmed CR or PR (the mITT population)
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Figure S3 shows the time to and duration of response in patients with confirmed CR or PR (the mITT population)
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Table S3 shows the biomarker results
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Table S3 shows the biomarker results
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary File 1 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary File 1 shows the Methods and Results for Part 1B
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 1 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary File 1 shows the Methods and Results for Part 1B
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Figure S2 shows the duration of treatment including response and tumor type (the safety analysis set)
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Figure S2 shows the duration of treatment including response and tumor type (the safety analysis set)
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Figure S1 shows the study design.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Supplementary Figure S1 shows the study design.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Supplementary Figure S1. Change from baseline in tumor biomarkers following monotherapy or combination treatment - biomarker analysis set.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Supplementary Figure S1. Change from baseline in tumor biomarkers following monotherapy or combination treatment - biomarker analysis set.